Pemvidutide vs UBT251

Head-to-head comparison of Pemvidutide (Pemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) and UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) — benefits, dosing, side effects, research data, and where to buy.

Research Score

PropertyPemvidutideUBT251
CategoryWeight ManagementWeight Management
Full NamePemvidutide (ALT-801), long-acting glucagon-like peptide-1/glucagon receptor dual agonistUBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist
Molecular WeightN/AN/A
Half-LifeApproximately 1 weekApproximately 1 week
Amino AcidsN/AN/A
Typical DoseTrial-dependent; once-weekly SC titrationInvestigational; no established human dose
RouteSubcutaneousSubcutaneous
Purity≥98%≥98%
Studies Count188
Research StatusClinicalPre-clinical

Pemvidutide Benefits

  • appetite suppression
  • body-weight reduction
  • improved liver-fat markers
  • better glycemic control

UBT251 Benefits

  • weight reduction
  • improved satiety
  • enhanced energy expenditure
  • better insulin sensitivity

Pemvidutide Dosing

once-weekly subcutaneous injection|gradual dose escalation|maintenance at tolerated trial dose

UBT251 Dosing

once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment

Pemvidutide Side Effects

  • nausea
  • vomiting
  • diarrhea

UBT251 Side Effects

  • nausea
  • diarrhea
  • fatigue

Research Overview

Pemvidutide

Clinical studies have reported dose-dependent weight loss and favorable effects on liver fat and transaminases. It remains investigational and is not approved for obesity treatment.

UBT251

Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.

Ready to buy?

Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.

Common Stacking Partners

Pemvidutide stacks with:

metformintopiramate

UBT251 stacks with:

metforminorlistat
glp1glucagondual-agonistobesitymashgiptriagonistweight-management